AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31891312 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 132
Study 28114980 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 120
Study 28114980 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 120
Study 27111333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) with standard stimulation pattern (with environmental sound perception)
Number of subjects: 10
Study 27111333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Implant (TI) with looped electrical stimulation (without environmental sound perception)
Number of subjects: 10
Study 25461783 — intervention group
Group type: EXPERIMENTAL
Intervention: Student Bodies with a guided discussion group (n = 74)
Number of subjects: 151
Study 25461783 — intervention group
Group type: COMPARATOR
Intervention: No discussion group (n = 77)
Number of subjects: 151
Study 21956605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg once daily
Number of subjects: 0
Study 21956605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 75 mg once daily
Number of subjects: 0
Study 21956605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 75 mg twice daily
Number of subjects: 0
Study 19727062 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews and meta-analyses
Number of subjects: 0
Study 17931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation (RADPLAT)
Number of subjects: 92
Study 17931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene Set Enrichment analysis
Number of subjects: 92
Study 17931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously published signatures for radiosensitivity, hypoxia, proliferation, 'wound,' stem cells, and chromosomal instability
Number of subjects: 92
Study 17931799 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently published signature for HNSCC defining a 'high-risk' group
Number of subjects: 92
Study 15826233 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant auditory sequence of digits presented in an incongruent order with the visual digits
Number of subjects: 0
Study 15826233 — intervention group
Group type: COMPARATOR
Intervention: Irrelevant auditory consonants
Number of subjects: 0
Study 15826233 — intervention group
Group type: EXPERIMENTAL
Intervention: Order-incongruence effect
Number of subjects: 0
Study 12047606 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoku-kan-san-ka-chimpi-hange (YKCH)
Number of subjects: 0
Study 9389260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% alone
Number of subjects: 46
Study 9389260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with clonidine 150 micrograms
Number of subjects: 46
Study 9389260 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with clonidine 150 micrograms i.m. (Control)
Number of subjects: 46
Study 7957155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing
Number of subjects: 25
Study 7957155 — intervention group
Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 25
Study 7957155 — intervention group
Group type: COMPARATOR
Intervention: Running
Number of subjects: 25
Study 7957155 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal rowing
Number of subjects: 25
Study 3298070 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (30 mg/kg/day for 10 days)
Number of subjects: 208
Study 3298070 — intervention group
Group type: COMPARATOR
Intervention: Vidarabine (15 mg/kg/day for 10 days)
Number of subjects: 208
Study 3298070 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 208
Study 3298070 — intervention group
Group type: COMPARATOR
Intervention: Vidarabine
Number of subjects: 208
Study 30576866 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa 0.3 mg/kg/d subcutaneously (SC) for 6 months
Number of subjects: 19
Study 30576866 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa 0.5 mg/kg/d SC for 6 months
Number of subjects: 19
Study 30576866 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa 0.5 mg/kg/d for 6 months, then 1 mg/kg/d 6 days/week for 4.5 years
Number of subjects: 19
Study 30576866 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa (combined group)
Number of subjects: 19
Study 30576866 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 19
Study 30130784 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical non‐medicated preparations including pH‐lowered preparations
Number of subjects: 0
Study 30130784 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive lipid barrier visualization (Lipbarvis®) technique
Number of subjects: 0
Study 26630618 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of evening meals
Number of subjects: 80
Study 26630618 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 24559157 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-546 (0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg/kg single dose; 0.3, 1.0, or 5.0 mg/kg/week for 4 weeks)
Number of subjects: 34
Study 24559157 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-546
Number of subjects: 34
Study 21766974 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine tablet
Number of subjects: 0
Study 21766974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21766974 — intervention group
Group type: COMPARATOR
Intervention: No-pill control condition
Number of subjects: 0
Study 19653752 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort manipulation (various conditions differing in environment, type of effort, and intention to act)
Number of subjects: 0
Study 19653752 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort manipulation with nonvisual (cognitive) factors considered
Number of subjects: 0
Study 17567339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 microg.kg(‐1)
Number of subjects: 75
Study 17567339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.0 microg.kg(‐1)
Number of subjects: 75
Study 17567339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microg.kg(‐1)
Number of subjects: 75
Study 17567339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2.0 microg.kg(‐1)
Number of subjects: 75
Study 17567339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 15167310 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.625 mg/d
Number of subjects: 2673
Study 15167310 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.625 mg/d + medroxyprogesterone acetate (MPA) 2.5 mg/d
Number of subjects: 2673
Study 15167310 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.45 mg/d
Number of subjects: 2673
Study 15167310 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.45 mg/d + medroxyprogesterone acetate (MPA) 2.5 mg/d
Number of subjects: 2673
Study 15167310 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.45 mg/d + medroxyprogesterone acetate (MPA) 1.5 mg/d
Number of subjects: 2673
Study 15167310 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.3 mg/d
Number of subjects: 2673
Study 15167310 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.3 mg/d + medroxyprogesterone acetate (MPA) 1.5 mg/d
Number of subjects: 2673
Study 15167310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2673
Study 11167328 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced T1-weighted black-blood fast spin-echo MR imaging (BB-FSE)
Number of subjects: 15
Study 11167328 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced T1-weighted SE
Number of subjects: 15
Study 9722068 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (1.0 g amino acid/m2/dose swish and swallow four times a day)
Number of subjects: 193
Study 9722068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine)
Number of subjects: 193
Study 9722068 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 193
Study 9722068 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 193
Study 8116534 — intervention group
Group type: EXPERIMENTAL
Intervention: High A (additional vitamin A in intravenous lipids)
Number of subjects: 0
Study 8116534 — intervention group
Group type: COMPARATOR
Intervention: Regular A (routine vitamin A supplementation)
Number of subjects: 0
Study 3122696 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2 in patients with panic disorders
Number of subjects: 33
Study 3122696 — intervention group
Group type: COMPARATOR
Intervention: 5% CO2 in healthy subjects
Number of subjects: 33
Study 3122696 — intervention group
Group type: COMPARATOR
Intervention: 7.5% CO2 in healthy subjects
Number of subjects: 33
Study 8458450 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin acetate 1,200 micrograms/d IN for 6 months (n = 19)
Number of subjects: 35
Study 8458450 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (n = 16)
Number of subjects: 35
Study 282081 — intervention group
Group type: EXPERIMENTAL
Intervention: active therapy
Number of subjects: 1017
Study 282081 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1017
Study 282081 — intervention group
Group type: COMPARATOR
Intervention: no tablets
Number of subjects: 1017
Study 282081 — intervention group
Group type: COMPARATOR
Intervention: non-study control group
Number of subjects: 1017
Study 30680523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1 and 80 mg on days 2-3)
Number of subjects: 24
Study 30680523 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant delayed 1-day administration (125 mg on day 2 and 80 mg on days 3-4)
Number of subjects: 24
Study 30680523 — intervention group
Group type: COMPARATOR
Intervention: Routine triple-antiemetic treatment
Number of subjects: 24
Study 30680523 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 24
Study 28357557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg/kg diluted to 10 mL with 0.9% saline)
Number of subjects: 330
Study 28357557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mL of 0.9% saline)
Number of subjects: 330
Study 28357557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.25 mg/kg)
Number of subjects: 330
Study 24902007 — intervention group
Group type: EXPERIMENTAL
Intervention: levomilnacipran extended-release (ER)
Number of subjects: 5
Study 24902007 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5
Study 24902007 — intervention group
Group type: EXPERIMENTAL
Intervention: levomilnacipran ER
Number of subjects: 5
Study 23320901 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 adjuvant therapy (three-week cycle)
Number of subjects: 200
Study 23320901 — intervention group
Group type: COMPARATOR
Intervention: S-1 adjuvant therapy (six-week cycle)
Number of subjects: 200
Study 21187138 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised herbal prescription
Number of subjects: 28
Study 21187138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19214679 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic ERCP procedures with nonnative papillae (Group A)
Number of subjects: 526
Study 19214679 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ERCP procedures with nonnative papillae (Group B)
Number of subjects: 526
Study 19214679 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic and therapeutic ERCP procedures with nonnative papillae (Groups A/B)
Number of subjects: 526
Study 16890769 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergen tablet (GRAZAX, ALK‐Abelló, Hørsholm, Denmark) once daily
Number of subjects: 634
Study 16890769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study 15345969 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (T group, n = 31)
Number of subjects: 62
Study 15345969 — intervention group
Group type: COMPARATOR
Intervention: Prolonged endotracheal intubation (I group, n = 31)
Number of subjects: 62
Study 15345969 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (T group) after pneumonia diagnosis
Number of subjects: 62
Study 15345969 — intervention group
Group type: COMPARATOR
Intervention: Prolonged endotracheal intubation (I group) after pneumonia diagnosis
Number of subjects: 62
Study 15345969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (T group and I group)
Number of subjects: 62
Study 11339775 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 375
Study 11339775 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-fructose-sucrose-maltose mixture (GFSM)
Number of subjects: 375
Study 11339775 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 375
Study 11339775 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 375
Study 11339775 — intervention group
Group type: COMPARATOR
Intervention: Control (overnight fast)
Number of subjects: 375
Study 9389379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine (5, 10, 20, 50 mg/kg i.v.)
Number of subjects: 47
Study 9389379 — intervention group
Group type: COMPARATOR
Intervention: Control pacing (placebo)
Number of subjects: 47
Study 7955799 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-383 administered as 1-hour infusion at 0.25 microgram/kg/min
Number of subjects: 56
Study 7955799 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-383 administered as 4-hour infusion at 0.15 microgram/kg/min
Number of subjects: 56
Study 7955799 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-383
Number of subjects: 56
Study 7955799 — intervention group
Group type: COMPARATOR
Intervention: Aspirin pretreatment (325 mg)
Number of subjects: 56
Study 3454679 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training combined with oral physostigmine
Number of subjects: 2
Study 3454679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 2
Study 31752916 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace sitting-reduction intervention
Number of subjects: 198
Study 31752916 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 31752916 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall changes
Number of subjects: 198
Study 31752916 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes outside of work
Number of subjects: 198
Study 27837048 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab early drug (week 0/1)
Number of subjects: 120
Study 27837048 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab late arms (week 8/9)
Number of subjects: 120
Study 27837048 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (early vs late)
Number of subjects: 120
Study 25421877 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP regimen (cisplatin 120 mg/m², doxorubicin 75 mg/m², methotrexate 12 g/m² × 2) pre-operatively followed by MAP or MAP with ifosfamide and etoposide post-operatively for patients with ≥10% viable tumour.
Number of subjects: 2260
Study 25421877 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP regimen followed by pegylated interferon for patients with <10% viable tumour.
Number of subjects: 2260
Study 25421877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (MAP regimen)
Number of subjects: 2260
Study 21917481 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive procedures (MI group)
Number of subjects: 43
Study 21917481 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (MT group)
Number of subjects: 43
Study 21809156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-No Birth Trainer
Number of subjects: 200
Study 18365794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 64
Study 16480570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural guided self-care with personalized feedback
Number of subjects: 61
Study 16480570 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural guided self-care without personalized feedback
Number of subjects: 61
Study 12351463 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin alone
Number of subjects: 88
Study 12351463 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus metformin
Number of subjects: 88
Study 12351463 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus troglitazone
Number of subjects: 88
Study 12351463 — intervention group
Group type: COMPARATOR
Intervention: Insulin plus metformin vs Insulin plus troglitazone
Number of subjects: 88
Study 9926890 — intervention group
Group type: EXPERIMENTAL
Intervention: Misgav Ladach method
Number of subjects: 50
Study 9926890 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel method
Number of subjects: 50
Study 7675941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 0
Study 7675941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7675941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.026 mg/kg
Number of subjects: 0
Study 2288138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake of less than 500 ml beverages per day
Number of subjects: 8
Study 2288138 — intervention group
Group type: COMPARATOR
Intervention: Fluid intake of more than 2500 ml beverages per day
Number of subjects: 8
Study 6986899 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate
Number of subjects: 0
Study 6986899 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone phosphate
Number of subjects: 0
Study 6986899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6986899 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate
Number of subjects: 0
Study 31848294 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose NaHCO3 (HD-NaHCO3; 0.8 meq/kg of lean body wt per day)
Number of subjects: 194
Study 31848294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose NaHCO3 (LD-NaHCO3; 0.5 meq/kg of lean body wt per day)
Number of subjects: 194
Study 31848294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 29223700 — intervention group
Group type: EXPERIMENTAL
Intervention: USSRO
Number of subjects: 31
Study 29223700 — intervention group
Group type: COMPARATOR
Intervention: BSSRO
Number of subjects: 31
Study 29223700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 27247409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay theory intervention
Number of subjects: 9500
Study 27247409 — intervention group
Group type: COMPARATOR
Intervention: Control materials
Number of subjects: 9500
Study 25449853 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-Strength (ES)
Number of subjects: 36
Study 25449853 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-Endurance (SE)
Number of subjects: 36
Study 25449853 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study 23034266 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen and Ozone injections
Number of subjects: 38
Study 23034266 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological anti-inflammatory treatment
Number of subjects: 38
Study 20484757 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic girls engaged in 21.7 minutes of MVPA per day; Perceived transportation barriers positively related to MVPA (+; P = .010)
Number of subjects: 1180
Study 20484757 — intervention group
Group type: EXPERIMENTAL
Intervention: Black girls engaged in 19.5 minutes of MVPA per day; BMI negatively related to MVPA (‐; P = .005), social support from friends positively related to MVPA (+; P = .006)
Number of subjects: 1180
Study 20484757 — intervention group
Group type: EXPERIMENTAL
Intervention: White girls engaged in 22.8 minutes of MVPA per day; BMI negatively related to MVPA (‐; P < .001), barriers negatively related to MVPA (‐; P = .012), social support from friends positively related to MVPA (+; P = .010), participation in school sports positively related to MVPA (+; P = .009), community sports positively related to MVPA (+; P = .025)
Number of subjects: 1180
Study 18194116 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, cyclosporine, and sirolimus for 3 months followed by mycophenolate mofetil
Number of subjects: 113
Study 18194116 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone, cyclosporine, and mycophenolate mofetil throughout the study
Number of subjects: 113
Study 16190913 — intervention group
Group type: EXPERIMENTAL
Intervention: IndoProCaf
Number of subjects: 54
Study 16190913 — intervention group
Group type: COMPARATOR
Intervention: nimesulide
Number of subjects: 54
Study 11833029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 43
Study 10333017 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized ITA grafts (n = 40)
Number of subjects: 80
Study 10333017 — intervention group
Group type: COMPARATOR
Intervention: Pedicled ITA grafts (n = 40)
Number of subjects: 80
Study 7473908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic antishock garment (PASG)
Number of subjects: 248
Study 7473908 — intervention group
Group type: COMPARATOR
Intervention: No-PASG
Number of subjects: 248
Study 7473908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic antishock garment (PASG) in blunt trauma subset
Number of subjects: 248
Study 1693038 — intervention group
Group type: EXPERIMENTAL
Intervention: Allylestrenol (ALE) 50 mg daily for 12 weeks
Number of subjects: 116
Study 1693038 — intervention group
Group type: COMPARATOR
Intervention: Chlormadinone acetate (CMA) 50 mg daily for 12 weeks
Number of subjects: 116
Study 7193005 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bromopride
Number of subjects: 10
Study 7193005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31985301 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005%/betamethasone dipropionate 0.064% foam (Cal/BD)
Number of subjects: 0
Study 31985301 — intervention group
Group type: COMPARATOR
Intervention: Halobetasol 0.01%/tazarotene 0.045% lotion (HP/TAZ)
Number of subjects: 0